Descripciones mejoradas de Syndetics:

The Vaccine Book: New Insights, Approaches and Technologies, Third Edition  provides comprehensive information on the current and future world of vaccines. It reveals the scientific opportunities and potential impact of vaccines, including economic and ethical challenges, problems encountered when producing vaccines, how clinical vaccine trials are designed, and how to introduce vaccines into widespread use. Although vaccines are now available for many diseases, there are still challenges ahead for major diseases such as AIDS, tuberculosis, and malaria. Edited by a new, highly experienced team of editors, the 3rd edition provides new approaches, design, and vaccine platform tools to develop vaccines quicker.

This new edition is fully updated and designed for students, researchers, public health offcials, and all others interested in increasing their understanding of vaccines.

Notas de autor provistas por Syndetics

Fabio Bagnoli is Senior Director at GSK, Research & Development. He is Discovery Project Leader & Translation Science Leader. As Discovery Project Leader he drives several teams composed of experts in all areas of research & development with the aim of discovering and developing new vaccines and monoclonal antibodies. As Translational Science Leader he is driving clinical research studies, biomarkers identification, and human organotypic modelling. Research conducted by Fabio led to the development of various vaccine candidates as well as filing of various patents and publications on different human pathogens. He has served as editor of several publications and as coordinator of industrial-academic efforts.

Rino Rappuoli is Senior Vice President, Head of Vaccine Research and Development at GSK. Previously, he served as visiting scientist at Rockefeller University and Harvard Medical School and held roles at Sclavo, Vaccine Research and CSO, Chiron Corporation, and Novartis Vaccines. He is Chief Scientist and Head External R&D, GSK Vaccines and has served as visiting scientist at Rockefeller University and Harvard Medical School. He is an elected member of the US National Academy of Sciences and the European Molecular Biology Organization. His awards include the Paul Ehrlich and Ludwig Darmstaedter Prize (1991), Italian President Gold Medal (2005), Albert Sabin Gold Medal (2009). In 2013 he was nominated third most influential person worldwide in the field of vaccines (Terrapin). In 2015 he was awarded Fellowship of Imperial College Faculty of Medicine London and the Maurice Hilleman Award.

Sanjay Phogat is Vice President at GSK, Research & Development. He is the Discovery Performance Unit (DPU) head. As DPU head along with his team, he drives the discovery portfolio which includes bacterial, fungal vaccines, and monoclonal antibodies against infectious diseases. Sanjay is an infectious diseases expert with over twenty years of experience and a strong understanding of vaccine research and development. Sanjay's unique experience covers a broad range of organizations varying from academia, government, not-for-profit, and pharma. He is scientific advisor for nonprofit organizations discovering antibodies for HIV and co-founder of Global Alliance of Indian biomedical professional and NIH visiting fellow committee. He has served as editor/co-editor/reviewer of several publications and has published over 80 scientific papers; many are highly cited and in very high impact journals.